Search

Your search keyword '"Receptors, Chimeric Antigen immunology"' showing total 29 results

Search Constraints

Start Over You searched for: Descriptor "Receptors, Chimeric Antigen immunology" Remove constraint Descriptor: "Receptors, Chimeric Antigen immunology" Region united states Remove constraint Region: united states
29 results on '"Receptors, Chimeric Antigen immunology"'

Search Results

1. Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023.

2. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

3. Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.

4. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.

5. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

6. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India.

8. FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.

9. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.

10. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

11. Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma.

12. Gastrointestinal infections and gastrointestinal haemorrhage are underestimated but serious adverse events in chimeric antigen receptor T-cell recipients: A real-world study.

13. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.

14. FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.

15. Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals.

16. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.

17. CAR-T cells, from principle to clinical applications.

18. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?

19. Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.

20. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.

21. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.

22. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.

23. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

25. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

26. The landscape of CAR T-cell therapy in the United States and China: A comparative analysis.

27. Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside.

28. Chimeric Antigen Receptor T-Cell Therapy.

29. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.

Catalog

Books, media, physical & digital resources